Category

Daily Briefs

Daily Brief Health Care: Tempus AI and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Tempus AI IPO: AI in Diagnostics at Scale, Investor Sentiment Appears Positive


Tempus AI IPO: AI in Diagnostics at Scale, Investor Sentiment Appears Positive

By Andrei Zakharov

  • Tempus AI, a healthcare IT company and provider of next-gen diagnostics, is expected to IPO next week. The company plans to raise $411M at the high end of the range.
  • The most recent S-1/A puts the expected price range per share at $35 to $37, implying a market cap of ~$6B at the midpoint.
  • Tempus AI provides personalized cancer care and brings AI to healthcare at scale. They train LLMs to develop AI applications and have the largest public genomic data sets in oncology

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Meituan, Jardine Cycle & Carriage and more

By | Consumer, Daily Briefs

In today’s briefing:

  • [Meituan (3690 HK, BUY, TP HK$156) TP Change]: Counting on Execution to Navigate the Uncertainties
  • Last Week in Event SPACE: Jardine Cycle & Carriage, “Name & Shame”, Asia Cement, Northern Minerals


[Meituan (3690 HK, BUY, TP HK$156) TP Change]: Counting on Execution to Navigate the Uncertainties

By Ying Pan

  • Meituan reported C1Q24 revenue 6.0%/6.2% higher our estimate/consensus, and adjusted net income 19%/29% higher than our estimate/consensus. The stock fell on lower takeout order and in-store revenue guidance for C2Q24;
  • The stock has two uncertainties:(1)Strategic moves by Douyin and Eleme,(2)success of overseas expansion. There are no easy answers to these two questions but we believe the corner has been turned
  • We maintain the stock as BUY rating and raise TP to HK$156/share to factor in the improvement in profitability.

Last Week in Event SPACE: Jardine Cycle & Carriage, “Name & Shame”, Asia Cement, Northern Minerals

By David Blennerhassett

  • A new tool highlights which TSE companies have disclosed a policy/consideration; sometimes referred to as the “name and shame” list. In practice, more “name” than “shame”. 
  • Jardine Cycle & Carriage (JCNC SP) is trading rich to its NAV. And the simple ratio (JCNC/Astra International (ASII IJ)) is the highest level outside the 2008 GFC. 
  • This is a rubbish Offer for Asia Cement China (743 HK). Given how shareholders voted at last year’s AGM, expect this Scheme to be voted down. Avoid.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Top 10 Highlights from the APAC PE, VC and Startup Ecosystem this Week – 09 Jun 2024

By | Private Markets, Smartkarma Newswire

Top ten highlights from the APAC PE, VC, and startup ecosystem this week:

  1. India’s General Elections Outcome: PM Narendra Modi’s NDA alliance scraped through with BJP losing outright majority, impacting stock market initially but later recovering as Modi secured the numbers for a third term.
  2. Private Equity and Venture Capital Landscape: Fund managers accumulating dry powder for deployment, with prominent launches of investment vehicles by seasoned managers like IFC’s Ruchira Shukla and Piyush Gupta.
  3. Startup Investments in India: Recouping with $1.9 billion raised in May, highest in nearly two years, including big-ticket deals with six startups securing over $100 million in funding.
  4. LP-GP Updates: Various investment activities reported, including Hades Financial’s commitment in India, Aura Group raising its first PE fund, and Patamar Capital’s credit fund targeting women-led enterprises in SE Asia.
  5. Infrastructure Investments: Coalition formed by KKR, GIP, and others to invest $25 billion in Indo-Pacific infrastructure, while Sunrise Capital KK and AHAM Asset Management announce fund raising for their respective ventures.
  6. Corporate Investments: Fubon Life Insurance committing $270 million in funds managed by KKR, Porsche Ventures securing first close of its debut Chinese VC fund, and China’s initiatives in solid-state battery technology for EVs.
  7. Startup Deals: Lenskart raises $200 million, Nium secures $50 million in funding, and ITM announces equity investment led by Temasek, among other investments in companies like Vigo Retail and Fibe.
  8. Going Public: Updates on IPOs with China tightening its grip on the stock market, S.F. Holding receiving regulatory approval for a secondary listing, and QuantumPharm eyeing IPO in Hong Kong to fuel global expansion.
  9. Market Moves: Bajaj Housing Finance approved filing for an IPO, Japanese startup Astroscale Holdings sees a successful listing, and EU retail industry pushing for protection against low-cost products from players like Shein.
  10. Deep Dives and Interviews: Analysis on alternative proteins, insight into consumer lending businesses of Southeast Asia’s tech giants, and profiles on startup ventures like Xanh SM in Indonesia and P2P lending platform Amartha in Indonesia.

APAC Private Markets Research

Explore latest Insights on APAC Private Markets on Smartkarma


Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Also, check out the latest in ECM Research on Smartkarma